ArticleEndocrine2009
Serum heart type fatty acid binding protein levels in metabolic syndrome.
Article in Endocrine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 61 citations in OpenAlex.
- Study of independent diagnostic efficacy and co-diagnostic strategies of molecular markers for diabetic cardiomyopathy.Frontiers in endocrinology · 2025Review
- H-FABP and Hs-cTnI Serum Concentrations Associate with the Development of Cardiovascular Events in Newly Diagnosed T2D, Pre-DM, and Normoglycemic Individuals.Vascular health and risk management · 2025Article
- Advances of research in diabetic cardiomyopathy: diagnosis and the emerging application of sequencing.Frontiers in cardiovascular medicine · 2024Review
- Potential clinical biomarkers and perspectives in diabetic cardiomyopathy.Diabetology & metabolic syndrome · 2023Review
- Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice.Biomedicines · 2023Review
- FABP3, FABP4, and heart rate variability among patients with chronic schizophrenia.Frontiers in endocrinology · 2023Article
- Metabonomic Characteristics of Myocardial Diastolic Dysfunction in Type 2 Diabetic Cardiomyopathy Patients.Frontiers in physiology · 2022Article
- The Relationship Between Menopause and Metabolic Syndrome: Experimental and Bioinformatics Analysis.Biochemical genetics · 2021Article
- Circulating Biomarkers for Cardiovascular Disease Risk Prediction in Patients With Cardiovascular Disease.Frontiers in cardiovascular medicine · 2021Review
- Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification-A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Review
- Prognostic utility of heart-type fatty acid-binding protein in patients with stable coronary artery disease and impaired glucose metabolism: a cohort study.Cardiovascular diabetology · 2020Article
- Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases.Metabolic syndrome and related disorders · 2020Review
- Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms.International journal of molecular sciences · 2019Review
- Fatty Acid Binding Protein 3 And Transzonal Projections Are Involved In Lipid Accumulation During In Vitro Maturation Of Bovine Oocytes.Scientific reports · 2017Article
- Diagnostic approaches for diabetic cardiomyopathy.Cardiovascular diabetology · 2017Review
- Heart-type fatty acid binding protein levels in elderly diabetics without known cardiovascular disease.Clinical interventions in aging · 2017Article
- Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease.Wiener klinische Wochenschrift · 2016Article
- E2F8 promotes hepatic steatosis through FABP3 expression in diet-induced obesity in zebrafish.Nutrition & metabolism · 2015Article
- Serum H-FABP levels in patients with hypothyroidism.Wiener klinische Wochenschrift · 2014Article
- Preoperative serum h-FABP concentration is associated with postoperative incidence of acute kidney injury in patients undergoing cardiac surgery.BMC cardiovascular disorders · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart type fatty acid binding protein (H-FABP) is a major cytoplasmic low-molecular weight protein and released into the circulation when the myocardium is injured. Previous studies have demonstrated that H-FABP is closely associated with acute coronary syndrome, hypertrophic and dilated cardiomyopathy, heart failure, stroke, obstructive sleep apnea syndrome, pulmonary embolism. The aim of this study was to investigate serum H-FABP value in the patients with metabolic syndrome (MetS). We measured serum H-FABP levels in 55 consecutive patients with MetS, and 73 age-matched control subjects by using a sandwich enzyme-linked immunosorbent assay. Serum H-FABP levels were significantly higher in patients with MetS than in control subjects 18.37 ± 13.0 and 7.9 ± 6.5 ng/ml, respectively, (P < 0.001). Serum H-FABP levels were significantly higher in patients with diabetic MetS than in without diabetic MetS, 24.0 ± 10.2 and 13.9 ± 12.6 ng/ml, respectively, (P: 0,003). There were statistically significant differences between patients without diabetic MetS and control subjects, 13.8 ± 12.6 and 7.9 ± 6.5 ng/ml, respectively, (P = 0.023). Patients with MetS have an increased risk of death from cardiovascular diseases. H-FABP seems to be a marker that will enable the detection of cardiac injury in the early asymptomatic period in patients with MetS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.